Opportunities with phage technology and antibody engineering of fusion proteins

Directed enzyme therapy has enormous potential for cancer treatment but is a complex and technically demanding approach requiring optimisation of several components. The choice of enzyme/prodrug combinations are reviewed elsewhere in this book and in this chapter we concentrate on the antibody/enzyme component. We consider the recent advances in protein engineering that have resulted in new methods of producing antibodies which may have major advantages when incorporated into ADEPT. In addition we review the progress with the new fusion protein approach and the prospects for the use of non-immunogenic antibody-enzymes.